Seeking committed partners for in-licensing or co-development opportunities for our therapeutic assets.
InnoMedica’s vision is to replace the systemic application of drugs with a targeted, and therefore gentler, approach by refining the most effective active ingredients into intelligent therapies using liposomal nanotechnology. The mission is therefore to enhance therapies for diseases with great therapeutic need, such as Parkinson’s or ALS, or to make therapy possible in the first place, to achieve real medical progress for the people affected.
Clinical Assets
Manufacturing, Technology, and IP
IP: strong patent protection, selected latest patents: 1) Liposomes comprising sphingomyelin WO2019122220A1 protecting the blood-brain barrier crossing capabilities of InnoMedica liposome technology (granted by USPTO in March 2023). 2) Liposomal compositions for use in a method of treating Parkinson’s disease, US2023210875A1 (published in July 2023).
Manufacturing: in-house manufacturing with a novel approach to lipid nanoparticle production, vertically integrated and fully GMP-compliant from procurement, raw material release, production, filling of final dosage form, quality control, quality assurance, cold-room storage, product release, and shipping.Advantage: in-house know-how built over 10 years of development time, active balancing of trade secrets versus patents, and currently unaffected by supply-chain disruptions.
Technology: newly developed lipid nanoparticle platform capable of efficient site-directed drug delivery, reaching unprecedented efficacy-toxicity profiles for existing and new molecular entities. The in-house manufacturing technology enables InnoMedica to produce a multiverse of highly functional lipid nanoparticles with the world’s smallest diameter of 30 nanometers.
PLOS Medicine 2025 – TLN-1 in Parkinson’s disease
Business Case Neurology – Fall 2025
